DREAMM-2: Assessing efficacy via indirect comparison of single-agent belantamab mafodotin versus selinexor plus dexamethasone combination in anti-CD38 exposed relapsed/refractory multiple myeloma (RRMM).

Rakesh Popat,Attaya Suvannasankha,Venediktos Kapetanakis,Thibaud Prawitz,Grammati Sarri,Rachel Elizabeth Hughes,Feng Wang,Cosima Hogea,Shannon Ferrante,Jenny Willson

DREAMM-2: Assessing efficacy via indirect comparison of single-agent belantamab mafodotin versus selinexor plus dexamethasone combination in anti-CD38 exposed relapsed/refractory multiple myeloma (RRMM).

2020

Rakesh Popat
Attaya Suvannasankha
Venediktos Kapetanakis
Thibaud Prawitz
Grammati Sarri
Rachel Elizabeth Hughes
Feng Wang
Cosima Hogea
Shannon Ferrante
Jenny Willson

e20527Background: Single-agent belantamab mafodotin (GSK2857916) is a first-in-class immunoconjugate targeting B-cell maturation antigen that demonstrated deep and durable responses in heavily pret...

Keywords:

Dexamethasone
Internal medicine
Oncology
indirect comparison
Medicine
Multiple myeloma
CD38
single agent
relapsed refractory
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations